Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis — Data Support Potential Use...
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) NEW HAVEN, Conn.–(BUSINESS WIRE)–Apr. 3, 2023– Rallybio Corporation (Nasdaq: RLYB) today announced that an...
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 – NCCN Guidelines...
COGENT BIOSCIENCES PRESENTS PRECLINICAL DATA AT AACR ANNUAL MEETING HIGHLIGHTING PRECISION THERAPY PIPELINE AND ANNOUNCES INITIATION OF PART 2 OF THE REGISTRATION-ENABLING APEX TRIAL WITH BEZUCLASTINIB IN ADVANCED SYSTEMIC MASTOCYTOSIS Preclinical data describes a...
Recent Comments